派博傳思國(guó)際中心

標(biāo)題: Titlebook: Higgs Particle(s); Physics Issues and E Ahmed Ali Book 1990 Springer Science+Business Media New York 1990 Boson.Kaon.Lepton.Meson.hadron [打印本頁(yè)]

作者: subcutaneous 時(shí)間: 2025-3-21 17:54
書目名稱Higgs Particle(s)影響因子(影響力)

書目名稱Higgs Particle(s)影響因子(影響力)學(xué)科排名

書目名稱Higgs Particle(s)網(wǎng)絡(luò)公開度

書目名稱Higgs Particle(s)網(wǎng)絡(luò)公開度學(xué)科排名

書目名稱Higgs Particle(s)被引頻次

書目名稱Higgs Particle(s)被引頻次學(xué)科排名

書目名稱Higgs Particle(s)年度引用

書目名稱Higgs Particle(s)年度引用學(xué)科排名

書目名稱Higgs Particle(s)讀者反饋

書目名稱Higgs Particle(s)讀者反饋學(xué)科排名

作者: 免除責(zé)任 時(shí)間: 2025-3-21 23:44

作者: 喚醒 時(shí)間: 2025-3-22 00:57

作者: Lamina 時(shí)間: 2025-3-22 04:58

作者: 我沒有命令 時(shí)間: 2025-3-22 10:39

作者: Dysarthria 時(shí)間: 2025-3-22 13:37
Overview: 978-1-4757-0910-0978-1-4757-0908-7

作者: 大罵 時(shí)間: 2025-3-22 17:58
https://doi.org/10.1007/978-1-4757-0908-7Boson; Kaon; Lepton; Meson; hadron

作者: offense 時(shí)間: 2025-3-22 22:12

作者: 輕推 時(shí)間: 2025-3-23 04:19

作者: flaggy 時(shí)間: 2025-3-23 07:16
Inventing an Elementary ParticleMy contribution to this workshop is history not physics. I shall give a personal account of the “invention” of what a British Sunday paper recently described as “the mythical Higgs’ particle”. I hope to have convinced you by my presence at this meeting that I am not a myth, even if the particle named after me is.

作者: osteocytes 時(shí)間: 2025-3-23 21:31

作者: SLAY 時(shí)間: 2025-3-24 02:07

作者: 跳脫衣舞的人 時(shí)間: 2025-3-24 05:45
Peter Higgs site-specific conjugationThis volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest

作者: 健談 時(shí)間: 2025-3-24 08:56
M. A. B. Bég site-specific conjugationThis volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest

作者: extrovert 時(shí)間: 2025-3-24 11:16
Pierre Binétruynters (DCTDC). The Developmental Therapeutics Program (DTP) of DCTDC promotes all aspects of the discovery and preclinical development of new compounds as drugs. Its activities include demonstration of antiproliferative activity in vitro through its 60 human tumor cell line screen and in vivo using

作者: Entrancing 時(shí)間: 2025-3-24 16:11
Christof Wetterich Similar incidences and death rates for the most important cancers are reported from other industrialized Western countries. Most patients diagnosed with cancer will receive one or more chemotherapy regimens during the course of their disease. Retrospective and prospective clinical trials have impro

作者: 易彎曲 時(shí)間: 2025-3-24 20:49
Howard E. Haber Similar incidences and death rates for the most important cancers are reported from other industrialized Western countries. Most patients diagnosed with cancer will receive one or more chemotherapy regimens during the course of their disease. Retrospective and prospective clinical trials have impro

作者: Insensate 時(shí)間: 2025-3-25 01:19

作者: 挑剔為人 時(shí)間: 2025-3-25 04:44
Graciela Gelminiastatic disease. Antineoplastic therapies designed to induce necrosis, apoptosis, or cytostasis of the malignant tissue are frequently toxic to normal tissues. Even with the serious adverse effects of many anticancer drugs, careful dosing, clinical monitoring, and prompt treatment of toxicity usuall

作者: effrontery 時(shí)間: 2025-3-25 10:32
R. S. Willeyastatic disease. Antineoplastic therapies designed to induce necrosis, apoptosis, or cytostasis of the malignant tissue are frequently toxic to normal tissues. Even with the serious adverse effects of many anticancer drugs, careful dosing, clinical monitoring, and prompt treatment of toxicity usuall

作者: Ostrich 時(shí)間: 2025-3-25 12:30

作者: 狼群 時(shí)間: 2025-3-25 17:38
Howard E. HaberAct of 1948, biologic products are mainly regulated by the Public Health Service Act of 1944. The differences in the regulation of drug and biologic products are mainly owing to the basic premise that most drug products have a known structure and are chemically synthesized, whereas biologic products

作者: opportune 時(shí)間: 2025-3-25 22:07
Michael E. ZellerAct of 1948, biologic products are mainly regulated by the Public Health Service Act of 1944. The differences in the regulation of drug and biologic products are mainly owing to the basic premise that most drug products have a known structure and are chemically synthesized, whereas biologic products

作者: Oration 時(shí)間: 2025-3-26 00:47
Stefano Bertolinil role that these enzymes play in cellular processes such as DNA replication, transcription and recombination (2) suggests that they may constitute logical targets in the design of antineoplastic agents. In fact, several useful antitumor agents have now been shown to function, at least in part, via

作者: 膝蓋 時(shí)間: 2025-3-26 06:20

作者: 出血 時(shí)間: 2025-3-26 12:14

作者: Optometrist 時(shí)間: 2025-3-26 13:00
Michael S. Chanowitzreatments aiming at several different targets are sought. Viral regulatory proteins, modified or not, appear ideal for this purpose because of their multimodal killing action against neoplastically transformed cells. The large nonstructural protein NS1of rodent parvoviruses is an excellent candidate

作者: Blanch 時(shí)間: 2025-3-26 16:59
J. F. Gunionbe instrumental for developing new therapies for cancer. This chapter highlights the rationale for combining biogerontology and cancer research to generate new strategies for cancer treatment. In particular, this chapter focuses on one gene, SIRT6, which has emerged as an important regulator of long

作者: insert 時(shí)間: 2025-3-27 00:21

作者: Frisky 時(shí)間: 2025-3-27 03:36
U. Baur expressed alone, outside the context of the virus, E4orf4 induces p53-independent cell-death in transformed cells. Oncogenic transformation of primary cells in tissue culture sensitizes them to cell killing by E4orf4, indicating that E4orf4 research may have implications for cancer therapy. It has

作者: 極大痛苦 時(shí)間: 2025-3-27 07:17

作者: Flatter 時(shí)間: 2025-3-27 10:49

作者: enterprise 時(shí)間: 2025-3-27 14:13

作者: fiction 時(shí)間: 2025-3-27 18:17

作者: Fortuitous 時(shí)間: 2025-3-27 23:50

作者: gusher 時(shí)間: 2025-3-28 02:27
Higgs Particles and Dark Matter Searchesal object of study of astronomy and astrophysics) can account for only a minor part of the mass in galaxies, small groups, clusters and superclusters of galaxies, and even at scales smaller than a galaxy, in globular clusters of stars. Most of the matter of the universe, up to 90%, of the total, is

作者: LUT 時(shí)間: 2025-3-28 10:01

作者: Prostatism 時(shí)間: 2025-3-28 13:33

作者: Ballad 時(shí)間: 2025-3-28 14:38
Searches for Light Scalar Particles in K Meson Decaysak interactions begins to address this problem by incorporating the Higgs mechanism of spontaneous symmetry breaking to give masses to the vector bosons. In its simplest formulation, the minimal model, there is a single doublet of scalar Higgs fields which, by its Yukawa coupling to fermion fields,

作者: indifferent 時(shí)間: 2025-3-28 20:46
Higgs Boson(s) and Rare B Processes : Theoretical Expectationshereafter referred to as the standard model, or SM), supplying us, at the same time, with strict guidelines for modelling viable extensions. After the successes linked to Kaon physics, of which the most recent is the first possible observation of “direct” CP violation in .. → . decays at CERN [1], t

作者: fender 時(shí)間: 2025-3-28 23:23

作者: 牲畜欄 時(shí)間: 2025-3-29 03:50
Testing the Higgs Mechanism at High Energy Colliderss of that physics that may emerge above 1 TeV at multi-TeV . colliders. Though there is no direct experimental evidence, the Higgs mechanism. is universally regarded as the only viable agent of .(2)..(1). symmetry breaking.. General considerations. based only on unitarity and gauge symmetry insure t

作者: 截?cái)?nbsp; 時(shí)間: 2025-3-29 08:06
Probing Higgs Bosons/Electroweak Symmetry Breaking in Purely Leptonic Channels at Hadron Collidersic final state modes are surveyed for both the Standard Model Higgs scenario and a variety of non-minimal Higgs sectors (the features of which are reviewed along the way). In particular, I examine the ability of the SSC to probe exotic Higgs scenarios using purely leptonic channels, and discuss the

作者: 邪惡的你 時(shí)間: 2025-3-29 13:53

作者: 充滿裝飾 時(shí)間: 2025-3-29 18:43

作者: Anal-Canal 時(shí)間: 2025-3-29 20:18
Hadronic and Muonic Branching Ratios for Decays of Light Higgs-Bosons.. But even if one extrapolates this result well beyond its range of validity, it still leads to a . for . which ranges from 40% at .. = 0.3 GeV. to 7% at .. = 2 GeV. It was then observed by Raby and West . that strong final state interactions could further enhance the rate for .→ ππ, and hence decr

作者: forecast 時(shí)間: 2025-3-30 02:00
Higgs Boson(s) and Rare B Processes : Theoretical Expectationsfr-x% fr-xb9adbaqaaeGaciGaaiaabeqaamaabaabaaGcbaGaamOqamaaBa% aaleaacaWGKbaabeaakiabgkHiTiqadkeagaqeamaaBaaaleaacaWG% Kbaabeaaaaa!3ABB!]] 作者: FECK 時(shí)間: 2025-3-30 06:57
Testing the Higgs Mechanism at High Energy Collidersat the electroweak interactions are not described by a gauge theory or that a breaking mechanism exists which is unimagined today. If the Higgs mechanism is confirmed than there may or may not be Higgs bosons, but there is necessarily a new force (the real #5) and associated new quanta.

作者: Ointment 時(shí)間: 2025-3-30 10:43

作者: 解決 時(shí)間: 2025-3-30 16:14
Graciela GelminiELs) do not have to be defined, and only minimal nonclinical proof-of-concept studies need to be provided. Nonetheless, the difficulty and importance of providing a relevant nonclinical safety assessment program is greatly increased because the first patients treated with a new oncology drug are mos

作者: certitude 時(shí)間: 2025-3-30 17:09
R. S. WilleyELs) do not have to be defined, and only minimal nonclinical proof-of-concept studies need to be provided. Nonetheless, the difficulty and importance of providing a relevant nonclinical safety assessment program is greatly increased because the first patients treated with a new oncology drug are mos

作者: Corporeal 時(shí)間: 2025-3-30 21:43
Hoi-Lai Yu or injuries to humans (.) .. Oncologic products classified as biologics include preventative and therapeutic vaccines, somatic cell and gene therapy, monoclonal antibodies, immunotoxins, radioimmunotherapy, recombinant proteins (e.g., cytokines, growth factors, and fusion proteins), and most other

作者: transient-pain 時(shí)間: 2025-3-31 02:54

作者: REP 時(shí)間: 2025-3-31 05:47

作者: 鬼魂 時(shí)間: 2025-3-31 10:50

作者: miracle 時(shí)間: 2025-3-31 14:45

作者: Climate 時(shí)間: 2025-3-31 19:05

作者: 槍支 時(shí)間: 2025-4-1 01:20

作者: MENT 時(shí)間: 2025-4-1 03:05
Scalar Particles in Superstring Models when the basic problems of this approach were identified: in particular the painfully large number of possible candidates and the issue of supersymmetry breaking. However, since one has started to address these problems, some definite progress has been made.

作者: 洞穴 時(shí)間: 2025-4-1 06:21

作者: nutrients 時(shí)間: 2025-4-1 11:17

作者: 飛鏢 時(shí)間: 2025-4-1 17:19
Peter Higgslume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.978-1-4899-9700-5978-1-4614-5456-4Series ISSN 2196-9906 Series E-ISSN 2196-9914

作者: 多余 時(shí)間: 2025-4-1 20:24

作者: tenuous 時(shí)間: 2025-4-1 23:51
J. F. Gunionerate new strategies for cancer treatment. In particular, this chapter focuses on one gene, SIRT6, which has emerged as an important regulator of longevity in mammals and appears to have multiple biochemical functions, which antagonize tumor development and may be useful in cancer prevention and treatment.

作者: ordain 時(shí)間: 2025-4-2 03:53

作者: Cholagogue 時(shí)間: 2025-4-2 08:43
Axions and Dilatons: The Search for Very Light Scalar Particlesa!44E3!]]

歡迎光臨派博傳思國(guó)際中心 (http://www.pjsxioz.cn/)

孝义市| 北安市| 五华县| 襄汾县| 阿坝县| 新蔡县| 神木县| 墨江| 托克托县| 新丰县| 衡阳市| 罗田县| 汉寿县| 栖霞市| 五常市| 定襄县| 承德县| 长治市| 大关县| 中方县| 五河县| 固安县| 凤庆县| 东至县| 昆明市| 新民市| 汕头市| 五原县| 孝感市| 措勤县| 临泉县| 高陵县| 合水县| 井陉县| 柘城县| 陆河县| 湖南省| 连平县| 岳西县| 香河县| 罗平县|